Across TCGA pan-cancer cohorts, LMNTD2 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of LMNTD2’s most consistent transcriptional readouts.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where LMNTD2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LMNTD2 is over-expressed in tumor, although a few such as THCA and LUAD show the opposite, repressed pattern.
KIRC, COAD, and THCA are the cancer types where LMNTD2 tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LMNTD2 RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.